Bedoya Felipe, Frigault Matthew J, Maus Marcela V
Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA 02114, USA; Harvard Medical School, Boston, MA 02115, USA.
Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA 02114, USA; Harvard Medical School, Boston, MA 02115, USA.
Mol Ther. 2017 Feb 1;25(2):314-320. doi: 10.1016/j.ymthe.2016.11.011.
Autologous T cells modified to recognize novel antigen targets are a novel form of therapy for cancer. We review the various potential forms of observed and hypothetical toxicities associated with genetically modified T cells. Despite the focus on toxicities in this review, re-directed T cells represent a powerful and highly effective form of anti-cancer therapy; we remain optimistic that the common toxicities will become routinely manageable and that some theoretical toxicity will be exceedingly rare, if ever observed.
经过改造以识别新型抗原靶点的自体T细胞是一种新型癌症治疗方法。我们综述了与基因改造T细胞相关的各种已观察到的和假设的潜在毒性形式。尽管本综述重点关注毒性，但重定向T细胞代表了一种强大且高效的抗癌治疗形式；我们仍然乐观地认为，常见毒性将变得常规可控，并且一些理论上的毒性即使被观察到也将极其罕见。
